Long-term use of pramipexole in the management of restless legs syndrome

Sleep Medicine

Volumn 13, Issue 10, 2012, Pages 1280-1285

  Lipford, Melissa C ^a   Silber, Michael H ^a  

^a Mayo Clinic College of Medicine   (United States)

Author keywords

Augmentation; Dopaminergic; Impulse control disorder; Pramipexole; Restless legs syndrome; RLS; Willis Ekbom disease

Indexed keywords

CLONAZEPAM; CODEINE; DEXTROPROPOXYPHENE; GABAPENTIN; HYDROCODONE; OXYCODONE; PRAMIPEXOLE; PREGABALIN; TEMAZEPAM; TRAMADOL;

ARTICLE; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DAYTIME SOMNOLENCE; DISEASE SEVERITY; DIZZINESS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPEPSIA; EVENING DOSAGE; FEMALE; HUMAN; IMPULSE CONTROL DISORDER; INSOMNIA; LIMB NUMBNESS; MALE; NAUSEA; NOSE OBSTRUCTION; PARESTHESIA; PRIORITY JOURNAL; QUALITY OF LIFE; RESTLESS LEGS SYNDROME; SINGLE DRUG DOSE; TREATMENT DURATION; TREATMENT RESPONSE;

BENZOTHIAZOLES; DOPAMINE AGONISTS; FEMALE; HUMANS; LONG-TERM CARE; MALE; MIDDLE AGED; RESTLESS LEGS SYNDROME; TREATMENT OUTCOME;

EID: 84870496023     PISSN: 13899457     EISSN: 18785506     Source Type: Journal    
DOI: 10.1016/j.sleep.2012.08.004     Document Type: Article

References (27)

1. Allen R.P., Picchietti D., Hening W.A., Trenkwalder C., Walters A.S., Montplaisir J., et al. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med 2003, 4:101-119.
2. Silber M.H., Girish M., Izurieta R. Pramipexole in the management of restless legs syndrome: an extended study. Sleep 2003, 26:819-821.
3. Earley C.J., Silber M.H. Restless legs syndrome: understanding its consequences and the need for better treatment. Sleep Med 2010, 11:807-815.
4. Montplaisir J., Boucher S., Poirier G., Lavigne G., Lapierre O., Lespérance P., et al. Clinical, polysomnographic, and genetic characteristics of restless legs syndrome: a study of 133 patients diagnosed with new standard criteria. Mov Disord 1997, 12:61-65.
5. Allen R.P., Stillman P., Myers A.J. Physician-diagnosed restless legs syndrome in a large sample of primary medical care patients in Western Europe: prevalence and characteristics. Sleep Med 2010, 11:31-37.
6. Allen R.P., Walters A.S., Montplaisir J., Hening W., Myers A., Bell T.J., et al. Restless legs syndrome prevalence and impact: REST general population study. Arch Intern Med 2005, 165:1286-1292.
7. Högl B., Kiechl S., Willeit J., Saletu M., Frauscher B., Seppi K., et al. Restless legs syndrome: a community-based study of prevalence, severity, and risk factors. Neurology 2005, 64:1920-1924.
8. Lavigne G.J., Montplaisir J.Y. Restless legs syndrome and sleep bruxism: prevalence and association among Canadians. Sleep 1994, 17:739-743.
9. Nichols D.A., Allen R.P., Grauke J.H., Brown J.B., Rice M.L., Hyde P.R., et al. Restless legs syndrome symptoms in primary care: a prevalence study. Arch Intern Med 2003, 163:2323-2329.
10. Phillips B., Hening W., Britz P., Mannino D. Prevalence and correlates of restless legs syndrome: results from the 2005 National Sleep Foundation Poll. Chest 2006, 129:76-80.
11. Tison F., Crochard A., Léger D., Bouée S., Lainey E., El Hasnaoui A., et al. Epidemiology of restless legs syndrome in French adults: a nationwide survey: the INSTANT Study. Neurology 2005, 65:239-246.
12. Allen R.P., Bharmal M., Calloway M. Prevalence and disease burden of primary restless legs syndrome: results of a general population survey in the United States. Mov Disord 2011, 26:114-120.
13. Silber M.H., Ehrenberg B.L., Allen R.P., Buchfuhrer M.J., Earley C.J., Hening W.A., et al. An algorithm for the management of restless legs syndrome. Mayo Clin Proc 2004, 79:916-922.
14. Kushida C.A. Pramipexole for the treatment of restless legs syndrome. Expert Opin Pharmacother 2006, 7:441-451.
15. García-Borreguero D., Allen R.P., Kohnen R., Högl B., Trenkwalder C., Oertel W., et al. Diagnostic standards for dopaminergic augmentation of restless legs syndrome: report from a World Association of Sleep Medicine-International Restless Legs Syndrome Study Group consensus conference at the Max Planck Institute. Sleep Med 2007, 8:520-530.
16. Nirenberg M.J., Waters C. Compulsive eating and weight gain related to dopamine agonist use. Mov Disord 2006, 21:524-529.
17. Weintraub D., Siderowf A.D., Potenza M.N., Goveas J., Morales K.H., Duda J.E., et al. Association of dopamine agonist use with impulse control disorders in Parkinson disease. Arch Neurol 2006, 63:969-973.
18. Johns M.W. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 1991, 14:540-545.
19. Kallweit U., Siccoli M.M., Poryazova R., Werth E., Bassetti C.L. Excessive daytime sleepiness in idiopathic restless legs syndrome: characteristics and evolution under dopaminergic treatment. Eur Neurol 2009, 62:176-179.
20. Montplaisir J., Fantini M.L., Desautels A., Michaud M., Petit D., Filipini D., et al. Long-term treatment with pramipexole in restless legs syndrome. Eur J Neurol 2006, 13:1306-1311.
21. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease. Arch Neurol 2009, 66:563-570. Parkinson Study Group, CCI.
22. Ondo W.G., Lai D. Predictors of impulsivity and reward seeking behavior with dopamine agonists. Parkinsonism Relat Disord 2008, 14:28-32.
23. Cornelius JR., Tippmann-Peikert M., Slocumb N.L., Frerichs C.F., Silber M.H. Impulse control disorders with the use of dopaminergic agents in restless legs syndrome: a case-control study. Sleep 2010, 33:81-87.
24. Silver N., Allen R.P., Senerth J., Earley C.J. A 10-year, longitudinal assessment of dopamine agonists and methadone in the treatment of restless legs syndrome. Sleep Med 2010, 12:440-444.
25. Winkelman JW., Johnston L. Augmentation and tolerance with long-term pramipexole treatment of restless legs syndrome (RLS). Sleep Med 2004, 5:9-14.
26. Allen R.P., Ondo W.G., Ball E., Calloway M.O., Manjunath R., Higbie R.L., et al. Restless legs syndrome (RLS) augmentation associated with dopamine agonist and levodopa usage in a community sample. Sleep Med 2011, 12:431-439.
27. Ondo W., Romanyshyn J., Vuong K.D., Lai D. Long-term treatment of restless legs syndrome with dopamine agonists. Arch Neurol 2004, 61:1393-1397.